Top Markets
Coin of the day
BioNexus Gene Lab Corporation BioNexus Gene Lab Corporation

BioNexus Gene Lab Corporation

BGLC
株式のランク #18714
BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on... BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming.
株価
$2.49
時価総額
$4.47M
変化(1日)
-4.01%
変化(1年)
678.16%
MY
取引 BioNexus Gene Lab Corporation (BGLC)

カテゴリー

BioNexus Gene Lab Corporation(BGLC)の利益
Sep 2025 時点の利益 TTM: $-2.37M
BioNexus Gene Lab Corporation の最新の財務報告によると、同社の現在の利益は $-2.37M です。2023 年には $-2.61M の利益を上げ、これは 2022 年の利益 $-303.66K と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
BioNexus Gene Lab Corporation の利益の推移(2016 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-2.37M 48.64%
2024 $-1.59M -38.84%
2023 $-2.61M 758.71%
2022 $-303.66K -129.12%
2021 $1.04M -17.40%
2020 $1.26M -557.92%
2019 $-275.71K -560.27%
2018 $59.90K -150.16%
2017 $-119.41K 14,201.08%
2016 $-835.00 0.00%
同業他社の利益
企業 利益 利益の差
$7.27B -306,699.14%
US
$4.23B -178,668.26%
US
$1.32B -55,960.65%
US
$2.63B -111,037.93%
CN
$1.43B -60,508.64%
US